Congenital Microtia in a Neonate Due to Maternal Isotretinoin Exposure 1 Month Before Pregnancy: Case Report Publisher Pubmed



Shirazi M^{1, 2} ; Abbariki E¹ ; Pirjani R¹ ; Akhavan S¹ ; Dastgerdy E² Show Affiliations
Source: Journal of Obstetrics and Gynaecology Research Published:2015

Abstract

Isotretinoin is a drug used for treating severe cystic/nodular acne. Severe malformations have been documented in neonates whose mothers had taken isotretinoin during pregnancy. Women who became pregnant one cycle after completing therapy are believed to be at teratogenic risk not higher than baseline. We describe the case of a newborn whose mother had taken the drug for 4 weeks. The woman then had contraception for 4 weeks (after the drug treatment had finished), and became pregnant after that period. The newborn had isolated bilateral microtia due to suspected isotretinoin exposure. His mother also had a history of urine tract infection in the second week of pregnancy that was treated with cephalexin. The parents were not from a consanguineous marriage and had no family history of congenital malformations. To reduce the risk, effective contraception should be continued in fertile women more than 1 month after completing therapy. © 2015 The Authors. Journal of Obstetrics and Gynaecology Research © 2015 Japan Society of Obstetrics and Gynecology.